You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: aspirin reduces the incidence of coronary artery disease in people at risk

https://doi.org/10.1136/ebm.6.6.171

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2001) Heart 85, 265. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE.. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.. Mar;. :. –71.
    OpenUrlAbstract/FREE Full Text

    
 
 QUESTION: In people at risk, what is the effectiveness of aspirin for primary prevention of coronary artery disease (CAD)?

    Data sources

    Randomised controlled trials from 1985 onward were identified by searching Medline with the terms cardiovascular disease and aspirin. Meta-analyses and review articles were also scrutinised.

    Study selection

    Studies were selected if they assessed the effectiveness of aspirin for primary prevention of CAD and assessed outcomes that included incidence of myocardial infarction (MI), stroke, all cardiovascular events (MI, stroke, and cardiovascular deaths), bleeding complications, and all-cause mortality.

    Data extraction

    Data were extracted on study sample size, patient characteristics, key components of the intervention, duration of intervention, and outcomes.

    Main results

    4 trials (48 540 patients) were included in the meta-analysis. 25 133 patients received aspirin, …

    View Full Text

    Footnotes

    • Theraputics

    • Source of funding: not stated.

    • For correspondence: Professor L E Ramsay, Clinical Pharmacology and Therapeutics, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK. Fax +44 (0) 114 272 1275.